Fig 1: ROC curve analysis of CEA, SCCAg, Cyfra21-1, CTAPIII/CXCL7, and biomarker combination in differentiating NSCLC patients and controls. Panels A&B: CEA, SCCAg, Cyfra21-1 and CTAPIII/CXCL7 in patients with lung adenocarcinoma versus controls in the training (A) and test sets (B). Panels C&D: CEA, SCCAg, Cyfra21-1 and CTAPIII/CXCL7 in patients with lung squamous cell carcinoma versus controls in the training (C) and test sets (D). Panels E&F: CEA, SCCAg, Cyfra21-1, CTAPIII/CXCL7 and biomarker combination in NSCLC patients versus controls in the training (E) and test sets (F).
Fig 2: Plasma CTAPIII/CXCL7 concentration in lung cancer patients and healthy controls. Panels A, training set; B, test set; C, full set; D, patients with lung adenocarcinoma; E, patients with lung squamous cell carcinoma. The black horizontal lines indicate median values. P values were based on Kruskal–Wallis nonparametric test and Nemenyi test.
Fig 3: ROC curve analysis of CEA, SCCAg, Cyfra21-1, CTAPIII/CXCL7, and biomarker combination in differentiating early stage NSCLC and controls. Panels A&B: CEA, SCCAg, Cyfra21-1, CTAPIII/CXCL7, and biomarker combination in stage I NSCLC patients versus controls in the training (A) and test sets (B). Panels C&D: CEA, SCCAg, Cyfra21-1, CTAPIII/CXCL7, and biomarker combination in stage Ia NSCLC patients versus controls in the training (C) and test sets (D).
Supplier Page from Abcam for Human CXCL7 ELISA Kit